What Hyperion Biosystems does

Hyperion Biosystems is a privately held diagnostic technology company founded in 2013 as an MIT 'Tough Tech' spinout (originally C2Sense, Inc.) and headquartered at 500 Arsenal St, Watertown, Massachusetts. The company develops diagnostic hardware and software that combine computer vision with proprietary physics-based and AI-enhanced algorithms to improve the sensitivity and specificity of rapid diagnostic assays. Its primary commercial platform, HALO, is a low-cost, fully connected reader system that integrates into partners' existing point-of-care and at-home testing products to identify false positives, delineate non-specific binding, and mitigate assay defects without requiring assay redesign — the company cites an average 10x sensitivity enhancement across more than 10,000 assays run on its algorithms. In January 2026, the company announced Helios, a rapid molecular diagnostic platform leveraging padlock probe chemistry, isothermal amplification, and optical readout to detect hundreds to thousands of targets simultaneously at single-copy sensitivity in under three hours using standard laboratory equipment.

The company's business model is B2B enterprise technology licensing and integration: Hyperion works directly with leaders in the point-of-care and at-home testing markets through direct enterprise sales, licensing its algorithms and HALO reader hardware, providing custom algorithm/professional services, and (more recently) licensing its time-gated luminescence on-dose authentication technology into the pharmaceutical supply chain via a partnership with Colorcon. Revenue streams include technology licensing/royalties, HALO reader hardware sales, and algorithm and software services. The company has secured non-dilutive support via two NIH RADx Tech awards (2022 and 2023) for the HALO platform, an $8M Series B in January 2023, additional equity funding through 2025, and partnerships with Princeton BioMeditech (OTC COVID/Flu at-home reader) and Colorcon (anti-counterfeiting). Customers and partners publicly named include Hycor Biomedical, Princeton BioMeditech, and Colorcon. The leadership team comprises CEO Jason Cox, Ph.D., CTO Robert Deans, Ph.D., and CSO Eric Keller, with a board that includes Dr. Michael Mina (MD/PhD), former Walgreens CMO Dr. Kevin Ban (Strategic Advisor), Jim Mahoney, Adam Behrens Ph.D., and Andrew Weber.

Name

Hyperion Biosystems

Legal name

Hyperion Biosystems

Website

https://hyperionbiosystems.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Hyperion Biosystems is an MIT spinout that builds computer vision and physics-based diagnostic readers and algorithms to improve sensitivity and specificity of point-of-care and at-home tests for diagnostic and pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Diagnostic Devices

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

akta.pro secondary industries

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Medical Imaging AI (HDAAAEAH)

Keywords

• Diagnostic devices
• Molecular diagnostics
• Computer vision algorithms
• Point-of-care testing
• Anti-counterfeiting technology

Headquarters

HQ city

Watertown

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Technology Licensing: Licensing proprietary diagnostic enhancement technology to diagnostic companies. Examples include licensing agreements with pharmaceutical partners for anti-counterfeiting technology.
2. Hardware Sales - HALO Reader: Sale of HALO diagnostic reader devices to partner companies for integration with their rapid diagnostic assays.
3. Algorithm and Software Services: Providing custom algorithm solutions to enhance existing diagnostic platforms without requiring partners to divert resources or redesign their assays.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Hyperion Biosystems designs and sells diagnostic devices and proprietary software that use computer vision and physics-based, AI-enhanced algorithms to improve the sensitivity and specificity of rapid diagnostic assays. The company partners with leaders in point-of-care and at-home testing markets to integrate its HALO diagnostic reader and algorithm platform into existing diagnostic offerings without requiring assay redesign, while also licensing on-dose anti-counterfeiting authentication technology for pharmaceutical and nutraceutical products.

Product overview

Hyperion Biosystems offers a suite of diagnostic technologies organized as two distinct core platforms. Halo is a low-cost, fully connected reader system for rapid diagnostic assays that uses physics-based, AI-enhanced algorithms to boost sensitivity and specificity. Helios is a next-generation rapid molecular diagnostic platform designed for highly multiplexed target detection at single-copy sensitivity. Both platforms leverage computer vision and physics-based algorithms as core enabling technologies, with Helios additionally utilizing padlock probe chemistry and isothermal amplification. The company works with leaders in point-of-care and at-home testing markets to improve diagnostic sensitivity and specificity.

Differentiator

Problem solved

Functional benefit

Brands

• Halo: A low cost, fully connected reader system for rapid diagnostic assays that simultaneously boosts sensitivity and specificity by leveraging physics-based, AI-enhanced algorithms. Identifies false positives, delineates non-specific binding and mitigates assay defects.
• Helios

Products and services

• HALO HALO is a low-cost, fully connected diagnostic reader system for rapid diagnostic assays. It uses a suite of physics-based, AI-enhanced algorithms to identify false positives, delineate non-specific binding, and mitigate assay defects, delivering higher assay performance without requiring redesign. It is sold to diagnostic companies for integration with their existing rapid diagnostic assays in point-of-care and at-home testing markets.
• Helios Helios is a rapid molecular diagnostic platform that enables simultaneous detection of hundreds to thousands of targets at single-copy sensitivity levels in less than three hours using standard laboratory equipment. It harnesses padlock probe chemistry, isothermal amplification, and an optical readout, and is intended for use by diagnostic and research laboratories.

Quantifiable outcome

• 10x average sensitivity enhancement through HALO platform
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• ColorconcoreOEM/ Whitelabel/ Licensing Partner · 13 May 2025Licensing agreement with Colorcon to commercialize and market a jointly-developed anti-counterfeiting technology for solid oral dosage pharmaceutical and nutraceutical products. Hyperion's technology enables on-dose authentication using low-cost CMOS cameras and delayed emission materials.
• Kevin BanminorOthers · 1 June 2024Dr. Kevin Ban, former Chief Medical Officer of Walgreens, joins Hyperion Biosystems Board of Directors as Strategic Advisor effective June 1, 2024.
• Michael MinaminorOthers · 24 May 2024Dr. Michael Mina, MD, Ph.D. joins the Board of Directors as an independent director effective May 24, 2024.
• Princeton BioMeditechcoreStrategic or Co-development Partner · 16 May 2023Partnership with Princeton BioMeditech to advance a digitally connected at-home diagnostic reader for sensitivity enhancement of OTC COVID-19/Flu A&B antigen tests. Received NIH RADx Tech funding to accelerate commercialization of PBM's Status COVID-19/Flu test used with C2Sense's Halo diagnostic reader. A second NIH RADx award was secured in April 2024 to continue the collaboration.
• Jim MahoneyminorOthers · 31 January 2023Jim Mahoney, MBA, MMA appointed as independent director to the Board of Directors effective January 31, 2023.
• Adam BehrensminorOthers · 31 January 2023Adam Behrens, Ph.D. joined the Board of Directors as an independent director effective January 31, 2023.
• Andrew WeberminorOthers · 31 January 2023The Honorable Andrew Weber appointed to the Board of Directors effective January 31, 2023.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• BioFire Diagnostics (bioMérieux): BioFire (owned by bioMérieux) is a market leader in multiplex molecular diagnostics through its FilmArray panels. Comparable to Hyperion's Helios platform in targeting syndromic and high-multiplex molecular testing at point-of-care, though BioFire is a much larger incumbent with FDA-cleared panels already deployed across hospital networks.
• Cepheid (Danaher): Cepheid (owned by Danaher) is the established leader in automated molecular diagnostics with its GeneXpert system. Comparable to Hyperion in the molecular diagnostics space where Helios competes, but Cepheid operates at much larger scale with broad installed base across hospitals and reference labs.
• GenMark Diagnostics (Roche): GenMark (now part of Roche) developed the ePlex system for multiplex molecular diagnostics at hospital point-of-care. Directly comparable to Hyperion's Helios in multiplex syndromic testing approach, but operates as part of a much larger diagnostics organization with broader assay menus and global reach.

Direct peers

• Visby Medical: Visby Medical develops rapid PCR-based point-of-care diagnostics for infectious disease. Comparable to Hyperion in targeting rapid, single-use molecular diagnostics outside traditional lab settings, with overlapping customer profiles in OTC and point-of-care testing markets served by HALO and Helios.
• Quanterix: Quanterix builds ultra-sensitive single-molecule detection platforms (Simoa) used in research and clinical diagnostics. Comparable to Hyperion's focus on sensitivity enhancement and single-copy detection, particularly Helios's claimed single-copy sensitivity, though Quanterix addresses protein biomarkers versus Helios's nucleic-acid targets.
• T2 Biosystems: T2 Biosystems develops diagnostic instruments (T2MR) for direct-from-sample molecular detection without sample prep. Comparable to Hyperion as a small-cap diagnostic instrument company focused on novel detection methods (magnetic resonance vs. Hyperion's optical/computer vision approach), serving similar hospital and clinical lab customers.
• Quantum-Si: Quantum-Si is developing next-generation protein sequencing platforms with single-molecule sensitivity. Comparable to Hyperion as a small-cap next-generation diagnostic platform company focused on ultra-sensitive detection, though Quantum-Si's technology targets proteomics rather than the molecular diagnostics space Helios addresses.
• Mesa Labs: Mesa Labs develops and manufactures quality assurance instruments and diagnostic tools including biological indicators and sterility assurance products. Comparable to Hyperion in operating as a specialty diagnostic instruments company with B2B sales to manufacturers and clinical end users, though Mesa has a much more diversified product portfolio.

Emerging players

• Opentrons Labworks: Opentrons provides accessible lab automation and is expanding into diagnostic workflows including COVID testing. Comparable to Hyperion as a smaller player targeting democratization of advanced diagnostics through affordable hardware and software, with some overlap in addressing the OTC and point-of-care testing markets.
• Paige.AI: Paige applies AI/computer vision to pathology and cancer diagnostics. Comparable to Hyperion in leveraging computer vision and AI to improve diagnostic accuracy beyond what conventional readers achieve, though Paige focuses on digital pathology image interpretation versus Hyperion's assay-result interpretation.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/hyperionbiosystems

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds9 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hyperion Biosystems